<SEC-DOCUMENT>0000313143-19-000016.txt : 20190514
<SEC-HEADER>0000313143-19-000016.hdr.sgml : 20190514
<ACCEPTANCE-DATETIME>20190514080301
ACCESSION NUMBER:		0000313143-19-000016
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20190514
ITEM INFORMATION:		Material Impairments
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190514
DATE AS OF CHANGE:		20190514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HAEMONETICS CORP
		CENTRAL INDEX KEY:			0000313143
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				042882273
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			0330

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14041
		FILM NUMBER:		19820488

	BUSINESS ADDRESS:	
		STREET 1:		400 WOOD RD
		CITY:			BRAINTREE
		STATE:			MA
		ZIP:			02184
		BUSINESS PHONE:		7818487100

	MAIL ADDRESS:	
		STREET 1:		400 WOOD ROAD
		CITY:			BRAINTREE
		STATE:			MA
		ZIP:			02184
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-kitem206.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s25CC1F5ACDFB5E6DBEE981EBC2254E4A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM&#160;8-K</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pursuant to Section&#160;13 OR 15(d)&#160;of The Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date of Report (Date of earliest event reported): May 13, 2019</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">HAEMONETICS CORPORATION</font></div><div style="line-height:120%;padding-bottom:4px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:91.40625%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:32%;"></td><td style="width:2%;"></td><td style="width:32%;"></td><td style="width:2%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Massachusetts</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">001-14041</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">04-2882273</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:4px;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction</font></div><div style="padding-bottom:2px;text-align:center;padding-left:4px;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;padding-left:4px;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer</font></div><div style="padding-bottom:2px;text-align:center;padding-left:4px;text-indent:1px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:80.6640625%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:56%;"></td><td style="width:2%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">400 Wood Road, Braintree, MA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">02184</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;">Registrant&#8217;s telephone number, including area code: </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">781-848-7100</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former name or former address, if changed since last report.)</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.140625%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:4%;"></td><td style="width:96%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Wingdings;font-size:11pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Wingdings;font-size:11pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Wingdings;font-size:11pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:Wingdings;font-size:11pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:94.53125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:39%;"></td><td style="width:19%;"></td><td style="width:42%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Securities registered pursuant to Section 12(b) of the Act:</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title of each class</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Trading Symbol(s)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name of each exchange on which registered</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Common stock, $.01 par value per share</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">HAE</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">New York Stock Exchange</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.3125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#231f20;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;color:#231f20;">Emerging Growth Company </font><font style="font-family:Wingdings;font-size:11pt;">o</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:11pt;">o</font></div></td></tr></table></div></div><div><a name="s8DE8552DE2575817B794A414D4632B4E"></a></div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;-sec-extract:summary;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Item 2.06  Material Impairments.</font></div><div style="line-height:100%;text-align:left;-sec-extract:summary;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:110%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">On May 13, 2019, Haemonetics Corporation (the &#8220;Company&#8221;) entered into a settlement, release and asset transfer agreement (the &#8220;Agreement&#8221;) with CSL Plasma Inc. (&#8220;CSL&#8221;), pursuant to which CSL will acquire substantially all of the tangible assets held by the Company relating to the manufacture of anti-coagulant and saline (together, &#8220;Liquids&#8221;) at the Company&#8217;s Union, South Carolina facility (&#8220;Union&#8221;), which consist primarily of property, plant and equipment and inventory, and will assume certain related liabilities as set forth in the Agreement (the &#8220;Asset Transfer&#8221;). The Asset Transfer excludes all other assets related to Union, including accounts receivable, customer contracts and the Company&#8217;s U.S. Food and Drug Administration (&#8220;FDA&#8221;) product approvals for manufacturing Liquids. </font></div><div style="line-height:110%;text-align:left;-sec-extract:summary;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:110%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Under the terms of the Agreement, upon closing, CSL will pay the Company approximately $10 million for the Asset Transfer and will concurrently release the Company from its obligations to supply Liquids under a 2014 supply agreement with CSL. In connection with the Asset Transfer, CSL and the Company will also enter into related transition services, supply and manufacturing service and quality agreements (the &#8220;Transition Agreements&#8221;) that will, among other things, permit CSL to manufacture Liquids under the Company&#8217;s FDA product approvals, exclusively for the Company and CSL, until CSL obtains separate product approvals from the FDA to manufacture the Liquids. CSL has also agreed to extend offers of employment to substantially all employees of the Company located at the Union facility.</font></div><div style="line-height:110%;text-align:left;-sec-extract:summary;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:110%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company will continue to supply Liquids to its customers following the Asset Transfer pursuant to the Company&#8217;s supplier arrangements with contract manufacturers. The Company expects that cost savings generated from the Asset Transfer, including the Company&#8217;s release from its Liquids supply obligations under the 2014 supply agreement with CSL, will be reallocated to general corporate purposes. </font></div><div style="line-height:110%;text-align:justify;-sec-extract:summary;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:110%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">In connection with its entry into the Agreement, the Company will classify the Union assets and liabilities related to the Asset Transfer under the Agreement as held-for-sale in its consolidated financial statements prior to the closing of the Asset Transfer. Accordingly, the Company will record such assets and liabilities at fair value, less estimated sales costs. As a result of the classification as&#160;held-for-sale,&#160;the Company will recognize an impairment charge on a U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) basis of approximately $49 million in the first quarter of fiscal 2020, primarily related to the carrying balances of the property, plant and equipment. The anticipated charge is not expected to result in any current or future cash expenditures. The Asset Transfer is expected to close in the first quarter of fiscal 2020 and is subject to the satisfaction of customary closing conditions.</font></div><div style="line-height:110%;text-align:justify;-sec-extract:summary;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:110%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">A copy of the Company&#8217;s press release announcing the Asset Transfer is attached to this Current Report on Form 8-K as Exhibit 99.1.</font></div><div style="line-height:100%;text-align:justify;-sec-extract:summary;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Item 7.01  Regulation FD Disclosure.</font></div><div style="line-height:100%;text-align:justify;-sec-extract:summary;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:110%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">The Company has updated its revenue (GAAP) and earnings per diluted share (GAAP) guidance and reaffirmed all other fiscal 2020 guidance previously reported in its May 7, 2019 earnings release to reflect the anticipated impact of the Asset Transfer. The updated guidance is available under the &#8220;Forecasts and Guidance&#8221; tab on the Investor Relations page on the Company&#8217;s website: www.haemonetics.com.</font></div><div style="line-height:100%;text-align:justify;-sec-extract:summary;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;text-align:justify;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Cautionary Note Regarding Forward-Looking Statements</font></div><div style="line-height:100%;text-align:left;-sec-extract:summary;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:110%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">This Current Report on Form&#160;8-K&#160;contains forward-looking statements about the Asset Transfer, including, but not limited to, statements related to the anticipated closing of the Asset Transfer, the Company's estimated charges and costs resulting from the Asset Transfer, including the expected timing thereof and expected classification of the assets and liabilities to be transferred to CSL upon closing, the Company&#8217;s expectation of cost savings resulting from the Asset Transfer and other statements that are not historical facts. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company&#8217;s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the risks that the Asset Transfer may not close in a timely manner or at all; the final impairment charge and other costs associated with the Asset Transfer may differ materially from what has been estimated by the Company at this time; the Company may incur additional costs and charges associated with the Asset Transfer; the Company may not realize the expected </font></div><div><br></div><div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:110%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-style:italic;">amount of the cost savings associated with the Asset Transfer for, among other reasons, CSL&#8217;s inability to timely obtain its own FDA product approvals to manufacture Liquids or either party&#8217;s inability to timely perform under the Transition Agreements. Investors should consult the Company's filings with the Securities and Exchange Commission (including the Company&#8217;s reports on Forms 10-K, 10-Q and 8-K) for information about additional risks and uncertainties that could cause the Company&#8217;s actual results to differ materially from these forward-looking statements. The Company undertakes no duty or obligation to update any forward-looking statements contained in this Current Report on Form&#160;8-K&#160;as a result of new information, future events or changes in its expectations.</font></div><div style="line-height:100%;-sec-extract:summary;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div style="line-height:100%;padding-bottom:16px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Item 9.01  Financial Statements and Exhibits.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">(d)  Exhibits</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:0px;text-indent:0px;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:95.12670565302143%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:11%;"></td><td style="width:2%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Exhibit Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Description</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:11pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="jointrelease51419.htm"><font style="font-family:inherit;font-size:11pt;">99.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Press release dated May 14, 2019</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s23CD31E225935130AE2BD5420A05A2CA"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:center;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0234375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:27%;"></td><td style="width:6%;"></td><td style="width:7%;"></td><td style="width:32%;"></td><td style="width:28%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">HAEMONETICS CORPORATION</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Date: May 14, 2019</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">/s/ Christopher A. Simon</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Name:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Christopher A. Simon</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">Title:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">President and Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>jointrelease51419.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3C6A176117D163F717BDB4029C5856EB"></a></div><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:center;text-indent:288px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font></div></div><div><br></div><div style="line-height:120%;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">Exhibit 99.1</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="release5919_image1.jpg" alt="release5919_image1.jpg" style="height:46px;width:196px;"></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:68px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="release5919_image2.jpg" alt="release5919_image2.jpg" style="height:49px;width:177px;"></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Arial;font-size:11pt;font-weight:bold;">FOR IMMEDIATE RELEASE</font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:14pt;"><font style="font-family:Arial;font-size:14pt;font-weight:bold;">HAEMONETICS TO TRANSFER UNION, SOUTH CAROLINA, MANUFACTURING FACILITY TO CSL PLASMA INC.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Braintree, Mass., and Boca Raton, Fla. &#8211; May 14, 2019 </font><font style="font-family:Arial;font-size:12pt;">- Haemonetics Corporation (NYSE: HAE) and CSL Plasma Inc. today announced an agreement to transfer ownership of Haemonetics&#8217; Union, South Carolina, manufacturing facility, operating assets and certain inventories to CSL Plasma. The facility produces liquid saline and sodium citrate, which are solutions used in the plasmapheresis, or plasma collection, process. CSL Plasma provides plasma to global biotechnology leader CSL Behring as the key raw material in developing and delivering life-saving medicines for people with rare and serious diseases &#8211; like immune deficiencies and bleeding disorders &#8211; in more than 60 countries around the world.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Under the terms of the agreement, at closing of the transaction CSL Plasma will obtain ownership and operational control of the facility, including property and equipment. In addition, through this transaction approximately 200 Haemonetics employees working in the Union, South Carolina, facility will be given the opportunity to become CSL Plasma employees.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Chris Simon, Haemonetics&#8217; President and CEO, commented, &#8220;This facility transfer&#160;is an important step in our asset optimization strategy, allowing us to&#160;improve our operating performance and&#160;focus on our core competencies. We will continue to redeploy our resources to invest in areas that hold the greatest potential for growth as we develop medical technology products and services that improve the quality, effectiveness and efficiency of patient care&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Mike Deem, CSL Plasma Inc. Senior Vice President and General Manager, added, &#8220;This transaction is an additional step to vertically integrate our supply chain, but more importantly, it provides CSL Plasma&#160;the ability to continue to deliver on its promise to patients who depend on life-saving therapy derived from plasma.&#8221;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">The transaction is expected to close within the current quarter, subject to the satisfaction of various closing conditions and a regulatory notification.&#160;Haemonetics also announced that it has updated its fiscal 2020 guidance assuming the closing of the transaction, which is available on the Haemonetics Investor Relations website.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">About Haemonetics </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.</font></div><div><br></div><div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;text-indent:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">About CSL Plasma Inc.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">CSL Plasma Inc., headquartered in Boca Raton, Florida, upholds a tradition of innovation and customer focus. We are committed to our work because people's lives depend on us. </font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">CSL Plasma is a subsidiary of CSL Behring, a global biotherapeutics company and a member of the CSL Group of companies. The parent company, CSL Limited (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 22,000 people, and delivers its life-saving therapies to people in more than 60 countries. For more information about CSL Plasma please go to www.CSLPlasma.com.&#160;</font></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;font-weight:bold;">Haemonetics Safe Harbor Statement </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;">Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this press release may include, without limitation, statements regarding the consummation of the agreement to transfer ownership of Haemonetics&#8217; Union, South Carolina, manufacturing facility and operating assets and statements by Haemonetics regarding the impact on its business strategy and future business and operational performance.&#160;Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon Haemonetics&#8217; current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, delays in consummation of the transaction or the transaction having an unanticipated impact. These and other factors are identified and described in more detail in Haemonetics&#8217; filings with the SEC. Haemonetics does not undertake to update these forward-looking statements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:39%;"></td><td style="width:61%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">HAE Investor Contacts</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Gerry Gould, VP-Investor Relations</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(781) 356-9402   </font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">gerry.gould@haemonetics.com    </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">HAE Media Contact</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Carla Burigatto, VP-Communications</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(781) 348-7263</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">carla.burigatto@haemonetics.com</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Olga Vlasova, Sr. Mgr.-Investor Relations</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(781) 356 9763</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">olga.vlasova@haemonetics.com</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:14px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CSL Investor Contact</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mark Dehring, VP Investor Relations</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">+61 39389 3407</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mark.Dehring@CSL.com.au</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">CSL Behring Media Contact</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Anthony Farina, VP Corporate Affairs &amp; Communications</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(302) 545-0316</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Anthony.Farina@CSLBehring.com</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>release5919_image1.jpg
<TEXT>
begin 644 release5919_image1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !& 2$# 2(  A$! Q$!_\0
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M_P"">IQH7BC_ *[0_P#H,E?#WQ&_Y*%KO_80N/\ T8U?Y_\ TNOXV%_Q3_\
M28GZ]PC_ +E'T_4QJ***_BL^J"OKG_@E1_R'?%G_ %PA_F:^1J^N?^"5!_XG
MOBS_ *X0_P S7ZOX*?\ )887_M[_ -)9S8K^$S@OBU_R57Q-_P!A:Z_]'/7/
MUT'Q:_Y*KXF_["UU_P"CGKGZ_P!">AX(4444""BBB@ HHHH **** "@?>_+^
M=% ^]^7\Z -[_@O#_P HOO#_ /U^Z7_Z):OPUK]RO^"\//\ P2^\/?\ 7[I?
M_HEJ_#6OGLU_C+T/[N^CE_R3$O\ KY+\HA1117F7/WX****+@%%%%%P"BBBB
MX!1111U _0#_ (-O?^3]=5_[%.[_ /2BUK]W*_"/_@V]/_&>VJ_]BG=_^E%K
M7[N5])E?^[H_@7Z0/_)73_P0_(****] _$3\R\48K])_[$L_^?2V_P"_2_X4
M?V'9X_X]+;_OTO\ A7WG^N<?^?7_ )-_P#XO_5/_ *>?A_P3\V,4$'%?I/\
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M*_23^Q[+_GUM_P#OTO\ A2_V-9X_X];?_OTO^% 6/S:Q0!\WUQ7Z2G1K,?\
M+K;?]^E_PH_L>R_Y];;_ +]+_A0%C\]_^"[I_P"-7OA_T^VZ7_Z):OPVK^L[
M4-%M=6M?(N;:"XAR"(Y8PZC'3@\52_X5_H0_Y@VE?^ J?X5Y^*P'MIJ5['[Q
MX;^,\>%<K>7/"^U;DY7YN7=?X6?R?45_6"?A_H0_Y@VE?^ B?X4#P!H1_P"8
M-I7_ (")_A7/_9/][\#]!_XF?C_T+_\ RI_]H?R?45_6%_PK[0Q_S!=*_P#
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M(OKD2^)/ RC2+Q7?]Y)"H_<2$<_P87/JGO7Y]?\ !R5,LW[>.B ,&V^#[0,
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MW5YU"27=Y?S2R,HX R6Z#THHI>R@XV:.R/$^;JN\4L3/VCTYN9W^^]R33?\
M@E?\&],T5=-MM%U>WL(UV+;Q:S=)$J^@4/@"NC_9U_X)_?"G]E7Q/?:YX(\,
MQZ1J>IP_9[B<3/(SIG=CYB>]%%5[*"V1%;B',ZM.5*IB)N,MUS.S]>Y5O?\
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+3ZMW84444&!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>release5919_image2.jpg
<TEXT>
begin 644 release5919_image2.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "" <L# 2(  A$! Q$!_\0
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MX'_X+Y?$JPT]HOB3^SSH>K77F96;0]:FT^,+Z%)4N23[[A]*Y,?\$)?VN_\
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M;<UDY.33:^!J7*]$U9W7[;4445]T?QJ?G%_P<!??^$O';7O_ ''U^<E?I/\
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M/VH_<[V:^3/X[X3X<Q?"7C1A<IQ+O*E62NMI)QYHRMK;FBT[=+V/R>K]8O\
M@A#_ ,FC>)/^RD7G_IOT^OR=K]8O^"$/_)HWB3_LI%Y_Z;]/KY7AG_D:K_"_
MT/Z0^D)_R;F?_7VG^;/M:BBBOT@_@L**** "OSC_ .#@+I\)?^X]_P"XZOT<
MK\X_^#@/I\)?^X]_[CJ\3B+_ )$]7_MW_P!*B?K/@;_R=++_ /N+_P"F*I^<
M=?7/[.W_  5\^+O[.7P9T/X+>'/A5X;U"RT.&2.&\OIK@2R;Y7D);:X'5R.!
MT%?(U>W?"W_@G-^V7\:/ >G_ !-^&GP:.I:'JL;/I]]_PD&G0^:JNR$[);A7
M7YE8<J.E?G^!J8^G5;PE^:VO*KNWW/K8_MSC/ \%YAET(<2NDJ*FG'VLU3CS
MV=K-RC=\O-I?:[MH=U\9?^"Q'[9'Q<\,2>$[#5]%\(P3,PGN_"-G-!=R(1]S
MSI9I&CQUW1>6V>^.*^5Z^GO"G_!'K]O/Q'K<>DZM\+]/T&&3.[4M6\26;01_
M46TDTG/LA]\5]$_L\_\ !"73],U*VU_]IWXHQ:DD,FZ3PYX3$B03%9%*B2[E
M59#&R!E9$CC<;@5E!'/H?V?GF9U$ZL9/SEHE]_Z(^,CQOX.^'^!G'+Z]&*>K
MCA[5)3>MKN%[M:VYY)+:ZN>1_P#!'+]D34OC!\;X?V@?%&FX\,>![P26IFA8
MK?:ILW0HAZ?N<K,S9R&$(P0Y*^X_\%\?^24_#[_L8KO_ -$+7W1X*\$>$/AO
MX5LO _@+PU9:/H^G1>78Z;I]NL4,*Y).%7CEB6)ZDDDY))KX7_X+X_\ )*?A
M]_V,5W_Z(6OH<7E\,MX>J4D[O1M]W=?AV/P?A[CG%\?>-V S"I'DIQ<HTX7O
MRP5.;U[RDVW)^=MDC\PZ_;S_ ()>_P#)AGPZ_P"P;<_^ED]?B'7[>?\ !+W_
M ),,^'7_ &#;G_TLGKRN$_\ ?I_X?U1^H?26_P"2+PO_ &$1_P#3=4]B^('P
M[\$?%;PK/X&^(WABTUG1[J:WENM,OX_,AG:&9)XPZ'AU$D:$JV58## @D':4
M!1M Z5YK^TW^UI\%/V2/!L7C#XP^(V@-X\D>E:391^;>:A(B[F2*/(Z C+L5
M12RAF4LN?SI^-/\ P7&_:2\:236'P:\)Z+X*LW6/R;J2,:E?1N"=QWRJ(=K<
M#:8"1_>.>/J\=FV7Y?+]Z_>MLE=VZ?\  NT?S7PAX:\;<<8=/ 4K8=2=IU)<
MM-2=E)QW<G[J4G",OA2>J2/U@KP[_@H_\)_#GQ<_8P\>:=X@MX_,T70;C7=-
MNOLZ/);7%E&UP"A8'875'A9A@^7-(,\FOR;\<_\ !0C]M;XA7<=[K_[2OBBW
M>.,(JZ'??V6A&>ZV8B4GW()KF-7_ &JOVG_$>DW6@:]^TCX^OK&^MGM[ZQN_
M&-[+#<0NI5XY$:4JZ,I*E2"""0>*\'%<48.M1G3]F[--:VZ_?^9^R</_ $=^
M*,IS/#8]X^E&I2G&=HJ;UC)/1M1OMU7R.#K]:/\ @A=JNI7_ .R#K-E?7TDT
M5CX^O(;..1LB&,VEG(47T&^1VQZL?6OR7K]8O^"$?_)I/B+_ +*->?\ I!I]
M>5PR[9HO1GZ5](2,9>',VUM5IV^]K\F?GG^W-X<U_P *_MD?$[2O$EI)#<2>
M-M0NXTDZFWN)FN(&^AAEC8>Q%7/V!/C-X'_9^_:[\&?%GXD3SPZ)IMU<Q7]Q
M;P&1H%N+2:V$I4')1&E#MC+;5;:K-A3]U?\ !6?_ ()T>(_C;))^TS\#---Y
MXEL-/6+Q%X;M;5?-U>"/.VXA*C=)<HF$\MMQEC1%3#1JDOY:RQ2P2M!/$R21
ML5=&7!5AU!'8US9AA\1E>9\]OM<T7T>MU]W4][@?/,E\1?#U82,]94?85H1=
MI0;AR2LG>RDKN$M4UYII?T6:)K>C>)M%L_$?AW5K:_T_4+6.YL;ZSG66&XA=
M0R2(ZDJZLI!# D$$$5:K\/?V0?\ @H5\>_V0-2AT_P -ZK_;GA7SE-WX2U>=
MVMPGF%G-LW)M)6WR?,H*EF#.DFU0/U=_9*_;I^ _[8>@F?X>:[]CUVVMS-JG
MA74V"7MHH?87 ^[+%DK^\C+ "1 ^QFV#[;+<\PN8VC\,^SZ^CZ_GY'\A^('A
M%Q)P+*6(<?;82^E6*V73VD=7!]+ZQ;LE*[L>RU^*?_!6?_E('\0/KI?_ *:K
M.OVLK\4_^"L__*0/X@?72_\ TU6=</%G_(OA_C7Y2/L/HU?\EUB?^P:?_IVB
M>%_#[P3K7Q+\>Z'\./#AA_M#Q!K%KIMA]HDVQ^=/*L2;C@X7<PR<' K]_/@_
M\*_"'P1^&&A_"?P'I_V?2="T^.UM5:-%>3 ^:638JJTKN6D=@!N=V8\DU^&7
M['7_ "=S\*_^RCZ'_P"E\-?OC7+PC3A[.K4MK=+Y?U^A]%])S,,5]<R_!<W[
MOEG.W>5U&[]$K+M=]SYQ_P""KWPML_B=^P]XND.DQW-]X=6#6M-D8G-NT$H\
MZ08(R?LSW"\Y&'/< C\5:_>3]N3_ ),W^*'_ &(FJ?\ I,]?@W7'Q9",<;"2
MZQ_)L^N^C3BJU3A+%T).\85KKRYH1NEV5U>W=M]3[2_X(F_L\>&_BO\ 'W6/
MBSXNL;.\M? -G;RZ?9W"EB-1N&D\B<*05/EI!,P)Y60Q,O*Y'ZS5^<7_  ;]
M_>^+G_<!_P#<C7Z.U]#PW3A3RF$DM9-M_>U^21^&^/6/Q6*\2\51JR;C2C3C
M!=$G3A-I>LI2?S/R._X+??#S2/"/[7=CXMT;2Q;MXH\)VUWJ4PF9OM%W%+-;
ME\,2%Q!%;+A0 =N<;BQ/QNXW(R^U?>/_  7K_P"2Y>!O^Q3E_P#2EZ^#Z^)S
MJ,89K52[W^_4_KKPCQ%7$^&^6SJ.[5/EWOI&3BE\DDEV6B/Z)/!/B:U\:^#-
M(\8V*;8=6TNWO(5SG"RQJX'Y-55_A?\ #Z7XC-\79_"5G)XF.DQZ6FM21;IX
MK-))9!"C'_5J7FD+;<;\KNSM7&5^SD?^,>O G_8FZ7_Z21UXA^VG_P %3_@Q
M^R=J4W@#0]+D\8>,8TS-I&GWBPV]@=R?+=7&'\MRI=A&B.WR8<1AU8_H];%8
M?#X>-7$-):.[[^7GZ'\$Y;P_GF<9]5RS):4YS;E&T7;W4[/FDVHJ.UW)J-[7
MUL?45%?C?X^_X+)?MS^,[^*[T/QIHGA>&.'8]GH/AV!XY6S]\F\$[ANWRL![
M=Z\DU']M/]K[5+N2]N?VH/'R/)(79;7Q9=PH"3GA(Y%51ST  '2O"J<68&+M
M"$G]R_4_8\O^C7Q?B*?-B\31I7Z)SF_1VBE]S9];_P#!?/P%X>TOQQ\.?B58
MZ<R:GK&G:C8:E<!CMDBM7MW@&.@8&YG^;J1M!X45^?=='X_^,7Q<^+ LQ\4_
MBIXD\3"P,AL!X@UVXO/L^_;O\OSG;9NVKG&,[1GH*YROCLRQ5/&XV=>"LI6T
M^23_ !U/ZJX#X=QG"?">&RG%555G24ES*]FG.4HI7U]V+4?EIH?T3>#O$-OX
MM\(Z7XJM$VPZGIL%W$OHLD:N!^1K2KC?V<_^3>_ ?_8FZ7_Z215V5?J].7-3
M3?5(_P U,=1CA\=5I1VC*27HFT?,'_!7OX.W?Q:_8JUJ^TJ"ZFOO".H6^OV]
MO;%?G2$/%<%]W\"6T\\AQSF,8ST/XS5_1?K.CZ3XBT>Z\/Z_IEO?6-];26][
M9W<*R17$+J5>-T8%65E)!4@@@X-?A3^VK^RUXA_9%^/FK?"[48II-)D8WGA?
M4)IED:[TYW;RF9E5?WBX,;C:OSHQ VE2?B^*\'+VD<3%:6L_T^_;Y']:?1MX
MLH3P.(X?K22G&3JTT^L6DIQ7^%I2MO[S>RT^CO\ @AQ^T/I_@7XQ:]\ /$E_
M)'!XSM4NM#,DTAC6^M5<O$$"E5:6%F8R$K_QZHGS%E _5&OYT-'UG6/#FKVO
MB#P]JMQ8ZA8W"7%C?6<S136\R,&21'4AD96 (8$$$9%?JQ^PY_P5\^%?Q5\,
MV?@7]IWQ+8^%?&%OB'^V+S$.G:LHC+><9<".UE^4[T<K&6*^6Q+^6FO#F;T8
M4?JM:5K?"WMKT];[?<>=X\>%^:XK-)<1Y52=6,TE6A%-RBXKE4U%:N+BDI65
MXM<ST;<?M>BJVCZSI'B+2[?7- U2WOK*ZA66UO+299(IHV&5=&4D,I!R""01
M5;Q;XS\(> ="F\4>.O%.G:+IMOS<:AJMZEO!%DX&YY"%'XFOL>:/+>^A_*T:
M56554XQ;DW:UM;[6MO?R-*BO'?A)^W7^SS\>/CMJ'P"^#_B6;7[_ $O0YM3O
M=9L8,Z<%BN(X&B28D&5\RHP:-6B*G(D)R!!^U1^W%\+_ -C[QEX-T3XNZ;J"
M:3XO6^7^VK&/SAI\ENUJ,RQ#YVC9;AB63<ZF, (V[*\[QF%C1=5S7*G9N^E[
MVW]6>W#A7B.IFE/+5A9_6)Q<XTW%J;BHN=U%V?PQ;2W=M$VT>TT5R?PH^.?P
M>^.6A+XC^$7Q)T?Q#:^7&\QTN^25[?>NY5E0'="^#RCA6'((!!%=83CDUO&<
M:D>:+NNZ/&Q&'Q&$K2HUX.$X[J2::]4]4>)_\%$_A7X.^*W[&GQ LO%VG+(V
MB^&[S6]+N%CC,EM>6D#S1R(SJ=A.TQL5PQCED0$;C7X9U^KW_!6[]O#P1\.?
MA+K7[,WP\\017_B_Q+:FRUH65PC+H]BY'G+-\K#S98]T0B^5@DID)7$8D_*&
MOS_BBM0J8Z*A9M*SMWOM\C^WOHZY7G&7\'5:N,BXTZM3FI*5TW'E2<TGM&3V
M?7EO:S3?VM_P0BFF7]K7Q) LK>6WPYNF://!87]A@_AD_F:^B_\ @N[_ ,FE
M^&_^RBVO_I!?UYE_P01^$DLFK>//CQ?Z;,L<=O!H&DWGFKY<C,PN+N/;][<H
M6R.3@8<@9.<>F_\ !=W_ )-+\-_]E%M?_2"_KTL+3G3X5GS=4VO2Y\#Q'C,/
MB_I'X6-)W]G*E%]N90N_NND^S370_)ZOUB_X(0_\FC>)/^RD7G_IOT^OR=K]
M7/\ @A/?V5M^R1XD2XNXXV/Q(O"%=@/^7"P']*\?AG_D:+_"_P!#].^D)=^'
M,[?\_:?YL^W**K_VOI7_ $$8?^_@H_M?2O\ H(P_]_!7Z/S(_@WEEV+%%1V]
MU;72EK:=9 IPQ1LX-24R0K\X_P#@X#Z?"7_N/?\ N.K]'*_./_@X#Z?"7_N/
M?^XZO$XB_P"1/5_[=_\ 2HGZSX&_\G2R_P#[B_\ IBJ?G'7[<_\ !+C_ ),,
M^'O_ %X77_I9/7XC5^W/_!+C_DPSX>_]>%U_Z63U\YPG_OT_\/ZH_H#Z2W_)
M&X7_ +"(_P#INH>_T445]\?Q,%? ?_!?'_DE/P^_[&*[_P#1"U]^5\!_\%\?
M^24_#[_L8KO_ -$+7CY__P BBK\O_2D?IW@S_P G,R[_ !2_]-S/S#K]O/\
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MKXF<+\#9/BL-FDIJ52HI+EBY*W*EKKW/./\ @W[^]\7/^X#_ .Y&OT=KQ/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P 0:;XCU2."^>XM8%1Y(XV;?<B39YBF(.6WA?\ 6!D$O;0#Y[T;0]&\._\
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MQ TGXY7_ /8_A;QZ;V?2M22)_L<<=U=BYM)G.W.Q,36S. 520L6(16<>I?\
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M +,>L7FO-!X?UK1--N=/MY(9+G4/[-WJL&X*Y.Z>-5; RW*Y&&/RQ_P1/_:
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M    ?,O_  6=\":/\+?^"?GP]^&7AV29]/\ #OB[2=,L7N&#2-#!I5]$A8@
M%MJC)P,GM7U9^QG_ ,F?_"G_ +)KH7_IO@I2^%#ZGI5?$?\ P7I_Y-"\-?\
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M")\4_P#!=;P?X2F_9@TGQY-X6TUM<@\86=E#K36,9NX[9H+IV@6;&\1E@&*
M[20#C->7_P#! CP=X0U?4/B-XQU;PKIMUJ^CS:6FDZI<6,;W-DLJ7JRB&4@M
M&'4 ,%(W  '-%%"^ /M'Z85^,/QZ^'?P_P!%_P""MUO\--'\"Z/:>'#\2-"M
M3X?MM+BCL3!(;3S(O(51'L;<VY=N#N.0<FBBBGU"1]+:_H>B^'O^"Z/@K1]
MT>UL;.U\,^3:VMG;K%'#&FB7B(BJH 55554 #   ' K]"***F0T><?MC#/[(
MOQ4!'_-.-<_]()J^</\ @A&JK^R3XD"KC_BY%WT_[!^GT44?9&=Q_P %<_"'
MA/7?V&O&WB76_"^G7FI:+!;/H^H75C')-8M)>6J2-"[ M$67Y6*D9'!R*^*_
M^"&?@_PEXL_:EUZY\5>%M-U*32?";7NE2:A8QS-97*WML%GB+@^7( Q =<,
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3&3Q7XG^5%_SR7_OFBBG#J#/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
